{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:40:19Z","timestamp":1784544019584,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Interdisciplinary Centre for Clinical Research, Jena University Hospital","award":["MSP15"],"award-info":[{"award-number":["MSP15"]}]},{"DOI":"10.13039\/100012957","name":"Friedrich-Schiller-Universit\u00e4t Jena","doi-asserted-by":"publisher","award":["FKZ Talent\/2023-06-01"],"award-info":[{"award-number":["FKZ Talent\/2023-06-01"]}],"id":[{"id":"10.13039\/100012957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:italic>N<\/jats:italic>,1,4-Tri(4-ethoxy-2-hydroxybenzyl)-1,4-diazepan-6-amine (TEoS-DAZA), a novel radiopharmaceutical precursor for a liver-specific <jats:sup>68<\/jats:sup>Ga-based diagnostic radiopharmaceutical, was tested for toxicity in rats to ensure its safe applicability and to fulfil the preclinical requirements in preparation of a clinical study. The study was performed according to EMA draft Guideline on the non-clinical requirements for radiopharmaceuticals, as well as to the so-called microdosing approach of the ICH guideline M3 (R2).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This randomized study was conducted using Wistar rats. The test item was administered intravenously at three different dose levels, the vehicle solution was administered to a separate group as control. Toxicity assessment included a 24\u00a0h observation period in three dose groups, and a 14-day recovery period in the high dose group. Animals were monitored regarding clinical behaviour, bodyweight, food and water consumption, additionally undergoing modified IRWIN, grip-strength and beam-walking tests. Following euthanisation, extensive haematological and clinical biochemical parameters were analysed. Necropsy and histopathology were performed. There was no evidence to any test-item related adversities at any dose level. No delayed effects were identified in any animal at the end of the recovery phase. Some small, albeit significant changes in haematology and clinical biochemistry could not be related to the test item administration. The NOAEL of TEoS-DAZA was determined at 1.4\u00a0mg\/kg bodyweight.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Administration of a thousandfold clinical dose of TEoS-DAZA in rats did not cause any observable adverse events. An injectable solution of [<jats:sup>68<\/jats:sup>Ga]Ga-TEoS-DAZA containing 100\u00a0\u00b5g of the precursor is safe for clinical application to humans from the pharmacological point of view. Subsequent dosimetry studies need to be undertaken to reveal any radiation related toxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41181-025-00342-x","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:26:16Z","timestamp":1747452376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Toxicity study of TEoS-DAZA, a chemical precursor for functional liver imaging with PET\/CT"],"prefix":"10.1186","volume":"10","author":[{"given":"Julia","family":"Greiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"F\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klopfleisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Steens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-3851","authenticated-orcid":false,"given":"Martin","family":"Freesmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"8","key":"342_CR1","first-page":"3019","volume":"99","author":"RJ Bergeron","year":"2002","unstructured":"Bergeron RJ, Wiegand J, Brittenham GM. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood, J Am Soc Hematol. 2002;99(8):3019\u201326.","journal-title":"Blood, J Am Soc Hematol"},{"key":"342_CR2","unstructured":"Consortium I. Recommended dose volumes for common laboratory animals. 2016."},{"key":"342_CR3","unstructured":"European Medicines Agency. ICH M3(R2) (2009) Guidance on nonclinical safety studies for the conduct of human clinical trials of and marketing authorization for pharmaceuticals. 11 June 2009."},{"key":"342_CR4","unstructured":"European Medicines Agency. Guideline on repeated dose toxicity. 2010, CPMP\/SWP\/1042\/99."},{"key":"342_CR5","unstructured":"European Medicines Agency. Guideline on the non-clinical requirements for radiopharmaceuticals. 2018 (Draft status), EMA\/CHMP\/SWP\/686140\/2018."},{"key":"342_CR6","unstructured":"European Medicines Agency. ICH Q3C (R9) Guideline on impurities: Guideline for residual solvents, April 2024."},{"key":"342_CR7","unstructured":"Food, Administration D. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Center for Drug Evaluation and Research (CDER). 2005;7(0.001)."},{"key":"342_CR8","unstructured":"Food, Administration D. Guidance for Industry: Q3C Tables and List, FDA, June 2017. Center for Drug Evaluation and Research (CDER). 2017;7(0.001)."},{"issue":"4","key":"342_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/diagnostics11040660","volume":"11","author":"M Freesmeyer","year":"2021","unstructured":"Freesmeyer M, Greiser J, Winkens T, G\u00fchne F, K\u00fchnel C, Rauchfu\u00df F, et al. Dynamic PET\/CT with the hepatobiliary tracer [68Ga] Ga-Tmos-DAZA for characterization of a hepatic tumor. Diagnostics. 2021;11(4):660.","journal-title":"Diagnostics"},{"issue":"1","key":"342_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/RLU.0000000000003719","volume":"47","author":"M Freesmeyer","year":"2022","unstructured":"Freesmeyer M, Drescher R, K\u00fchnel C, G\u00fchne F, Greiser J. Hepatobiliary excretion PET\/CT With 68Ga-TAoS-DAZA to evaluate bile duct patency. Clin Nucl Med. 2022;47(1):59\u201360.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"342_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00259-024-06895-4","volume":"52","author":"M Freesmeyer","year":"2024","unstructured":"Freesmeyer M, Greiser J, Drescher R, Settmacher U, Rohland O, Dondorf F. PET\/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak. Eur J Nucl Med Mole Imaging. 2024;52(2):787\u20139. https:\/\/doi.org\/10.1007\/s00259-024-06895-4.","journal-title":"Eur J Nucl Med Mole Imaging"},{"issue":"2","key":"342_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1037\/0735-7044.104.2.320","volume":"104","author":"LB Goldstein","year":"1990","unstructured":"Goldstein LB, Davis JN. Influence of lesion size and location on amphetamine-facilitated recovery of beam-walking in rats. Behav Neurosci. 1990;104(2):320.","journal-title":"Behav Neurosci"},{"issue":"27","key":"342_CR13","doi-asserted-by":"publisher","first-page":"9000","DOI":"10.1039\/C8DT01038B","volume":"47","author":"J Greiser","year":"2018","unstructured":"Greiser J, K\u00fchnel C, G\u00f6rls H, Weigand W, Freesmeyer M. N,1,4-Tri (4-alkoxy-2-hydroxybenzyl)-DAZA: efficient one-pot synthesis and labelling with 68 Ga for PET liver imaging in ovo. Dalton Trans. 2018;47(27):9000\u20137.","journal-title":"Dalton Trans"},{"issue":"12","key":"342_CR14","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.3390\/pharmaceutics14122695","volume":"14","author":"J Greiser","year":"2022","unstructured":"Greiser J, Winkens T, Perkas O, Kuehnel C, Weigand W, Freesmeyer M. Automated GMP production and preclinical evaluation of [68Ga] Ga-TEoS-DAZA and [68Ga] Ga-TMoS-DAZA. Pharmaceutics. 2022;14(12):2695.","journal-title":"Pharmaceutics"},{"issue":"2","key":"342_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3181\/00379727-186-42604","volume":"186","author":"AS Hassan","year":"1987","unstructured":"Hassan AS. The effect of dimethyl sulfoxide on cholesterol and bile acid metabolism in rats. Proc Soc Exp Biol Med. 1987;186(2):205\u201310.","journal-title":"Proc Soc Exp Biol Med"},{"key":"342_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/BF00401402","volume":"13","author":"S Irwin","year":"1968","unstructured":"Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968;13:222\u201357.","journal-title":"Psychopharmacologia"},{"key":"342_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-016-0004-6","volume":"1","author":"J Koziorowski","year":"2017","unstructured":"Koziorowski J, Behe M, Decristoforo C, Ballinger J, Elsinga P, Ferrari V, et al. Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2017;1:1\u20136.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"342_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102046","volume":"60","author":"M Kurakula","year":"2020","unstructured":"Kurakula M, Rao GK. Pharmaceutical assessment of polyvinylpyrrolidone (PVP): as excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. J Drug Deliv Sci Technol. 2020;60: 102046.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"342_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/taap.1996.8009","volume":"142","author":"RC Lind","year":"1997","unstructured":"Lind RC, Gandolfi AJ. Late dimethyl sulfoxide administration provides a protective action against chemically induced injury in both the liver and the kidney. Toxicol Appl Pharmacol. 1997;142(1):201\u20137.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"342_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/019262339902700310","volume":"27","author":"RC Lind","year":"1999","unstructured":"Lind RC, Gandolfi AJ. Hepatoprotection by dimethyl sulfoxide. I. Protection when given twenty-four hours after chloroform or bromobenzene. Toxicol Pathol. 1999;27(3):342\u20137.","journal-title":"Toxicol Pathol"},{"issue":"3","key":"342_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/0023677213516312","volume":"48","author":"M M\u00e4hler","year":"2014","unstructured":"M\u00e4hler M, Berard M, Feinstein R, Gallagher A, Illgen-Wilcke B, Pritchett-Corning K, et al. FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Lab Anim. 2014;48(3):178\u201392.","journal-title":"Lab Anim"},{"issue":"4","key":"342_CR22","first-page":"566","volume":"44","author":"P Montaguti","year":"1994","unstructured":"Montaguti P, Melloni E, Cavalletti E. Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains. Arzneimittelforschung. 1994;44(4):566\u201370.","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"342_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/109158189801700408","volume":"17","author":"B Nair","year":"1998","unstructured":"Nair B. Final report on the safety assessment of polyvinylpyrrolidone (PVP). Int J Toxicol. 1998;17(4):95\u2013130.","journal-title":"Int J Toxicol"},{"issue":"1","key":"342_CR24","first-page":"25","volume":"45","author":"GR Ruble","year":"2006","unstructured":"Ruble GR, Giardino OZ, Fossceco SL, Cosmatos D, Knapp RJ, Barlow NJ. The effect of commonly used vehicles on canine hematology and clinical chemistry values. J Am Assoc Lab Anim Sci. 2006;45(1):25\u20139.","journal-title":"J Am Assoc Lab Anim Sci"},{"issue":"9","key":"342_CR25","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/j.transproceed.2004.09.057","volume":"36","author":"M Sahin","year":"2004","unstructured":"Sahin M, Avsar FM, Ozel H, Topaloglu S, Y\u0131lmaz B, Pasaoglu H, et al. The effects of dimethyl sulfoxide on liver damage caused by ischemia-reperfusion. Transp Proc. 2004;36(9):2590\u20132. https:\/\/doi.org\/10.1016\/j.transproceed.2004.09.057.","journal-title":"Transp Proc"},{"key":"342_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2021.213908","volume":"438","author":"F Travagin","year":"2021","unstructured":"Travagin F, Lattuada L, Giovenzana GB. AAZTA: the rise of mesocyclic chelating agents for metal coordination in medicine. Coord Chem Rev. 2021;438: 213908.","journal-title":"Coord Chem Rev"},{"issue":"2","key":"342_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1091581810391818","volume":"30","author":"K Weber","year":"2011","unstructured":"Weber K, Razinger T, Hardisty JF, Mann P, Martel KC, Frische EA, et al. Differences in rat models used in routine toxicity studies. Int J Toxicol. 2011;30(2):162\u201373.","journal-title":"Int J Toxicol"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00342-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:26:23Z","timestamp":1747452383000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00342-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00342-x","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out under a protocol approved by the institutional ethics commitee of vivo Science and authorized by the State Agency for Nature, Environment and Consumer Protection (Landesamt f\u00fcr Natur, Umwelt und Verbraucherschutz; LANUV, no. 81-02.04.40.2023.VG016\/001). The study was conducted in accordance with the ARRIVE guidelines and in accordance with the European directives on the protection and use of animals used for scientific purposes (Council Directive 2010\/63\/EU) and the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes of the Council of Europe (Directive ETS No. 123, 1986, Appendix A (2006)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Julia Greiser and Martin Freesmeyer are the inventors of the patented test item (WO2019115429 A1). This patent is owned by x-nuclear Diagnostics GmbH. inflamed pharma GmbH (employee Beatrice Engert) holds a patent pending on the solubilized formulation of the test item. Vivo Science GmbH (employees Marion Hecht and Rebecca Steens) was paid by inflamed pharma GmbH for carrying out the study. Roman F\u00f6ll and Robert Klopfleisch acted as consultants for study design and implementation and were paid for this service by inflamed pharma GmbH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}